Wyeth

Wyeth Holdings Corporation

Praxis Biologics, Inc.

University of Colorado

University of Missouri

Bactex, Inc.

The United States of America, As Represented by the Uniformed Services University of Health Sciences

American Cyanamid Company

American Cyanamid Co. and Bactex, Inc.

Praxis Biologies, Inc.

The United States of America As Represented by the Uniformed Services University of the Health Sciences

Gary W. Zlotnick

Bruce A. Green

Bruce Arthur Green

Gary Warren Zlotnick

Kathrin Ute Jansen

Annaliesa Sybil Anderson

Viliam Pavliak

Ingrid Lea Scully

Michael G Jobling

Randall K Holmes

Amy Wadhams Masi

Jasdeep Singh Nanra

Robert A Deich

Duzhang Zhu

Mark Edward Ruppen

Charles C Brinton, Jr

Steven Morris Baker

Ellen Murphy

Yekaterina Timofeyeva

Leah Diane Fletcher

Robert J Zagursky

A Krishna Prasad

Arnold L Smith

Algis Anilionis

Joseph Lawrence Wooters

Robert C Seid, Jr

Stephen John Freese

Deb Narayan Chakravarti

Tracy Dee Scott

David Parrish Russell

Thomas J Reilly

John Hayward Eldridge

Gerald E Hancock

Ingrid Lea Dodge

Joel A Peek

Robert C Seid

The present invention relates to immunogenic conjugates comprisingserotype 5 and 8 capsular polysaccharides conjugated to carrier proteins and methods for their preparation and use. Methods for making the immunogenic conjugates of the invention involve covalent conjugation of the capsular polysaccharides with the carrier proteins using conjugation chemistry involving either 1,1-carbonyl-di-1,2,4-triazole (CDT) or 3-(2-pyridyldithio)-propionyl hydrazide (PDPH).

[object Object]

The present invention relates to immunogenic conjugates comprisingserotype 5 and 8 capsular polysaccharides conjugated to carrier proteins and methods for their preparation and use. Methods for making the immunogenic conjugates of the invention involve covalent conjugation of the capsular polysaccharides with the carrier proteins using conjugation chemistry involving either 1,1-carboyl-di-1,2,4-triazole (CDT) or 3-(2-pyridyldithio)-propionyl hydrazide (PDPH).

The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from. The present invention also relates to immunogenic compositions, comprisingcapsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects againstusing immunogenic compositions of thepolypeptides and capsule polysaccharides.

The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of, wherein the open reading frames encode polypeptides that are surface localized on. Thus, the invention relates toopen reading frames that encode polypeptide antigens, polypeptides, preferably antigenic polypeptides, encoded by theopen reading frames, vectors comprising open reading frame sequences and cells or animals transformed with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosinginfection. The invention finally relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with. In particular embodiments, the immunogenic compositions are used for the treatment or prevention of systemic diseases which are induced or exacerbated by. In other embodiments, the immunogenic compositions are used for the treatment or prevention of non-systemic diseases, particularly of the otitis media, which are induced or exacerbated by

The present invention discloses amino acid sequences and nucleic acid sequences relating to asurface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to compositions for the treatment and prophylaxis of infection or inflammation associated with bacterial infection.

A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable(NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination with additional antigens, are also provided.

Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

Mutant forms of cholera holotoxin as an adjuvant

A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus or parasite. In a particular embodiment, the amino acid 29 is histidine. The mutant cholera holotoxin may contain at least one additional mutation in the A subunit at a position other than amino acid 29. The antigenic composition may include a second adjuvant in addition to the mutant cholera holotoxin.

Mutant cholera holotoxin as an adjuvant

Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

Growing community of inventors

New City, NY, United States of America

Bruce Arthur Green